The research focuses involve IDH mutation, 1P/19Q combined deletion, MGMT promoter methylation, etc. Many studies have shown that IDH mutation is a common initial factor in all types of gliomas, and high-grade glioma patients with IDH mutation have a significantly better prognosis than those without mutation (Leu et al., 2016). The gene discussed is MGMT; the disease is central nervous system cancer.